2001 Saab 9-5 2.3t Sedan 4-door 2.3l on 2040-cars

Auto blog

This virtually new, very last Saab 9-3 could be yours

The date is October 7, 2019, and it is currently possible to buy a virtually new 2014 Saab 9-3 Aero Turbo4. Spiking the car's rarity is the fact that this specific vehicle is said to be the last Saab to roll off the production line in Trollhattan, Sweden. Driven only 41 miles, chassis No. YTNFD4AZXE1100257 is a true piece of Swedish automotive history, and it's set for auction this month. We first got word of this car back in June 2019, and the time has finally come for this Saab to be sold. As previously reported, this vehicle is from the National Electric Vehicle Sweden (NEVS) era. The seller, Bilweb Auctions, says it is the last Saab to come off the manufacturing line, and it was reportedly set aside for crash testing. The testing never occurred, and the sedan, one of only 420 built, survived. The seller says the mileage comes from running the car on the test track next to the old plant for photography and videography purposes.  This 9-3 Aero uses a Ecotec 2.0-liter turbocharged four-cylinder with 217 horsepower and 258 pound-feet of torque. It has immaculate Diamond Silver paint and matching silver turbine wheels. Inside, there is a two-tone interior with cream leather seats, a black dashboard, and black accents. According to Autocar, the proceeds of the auction will go to NEVS' Sustainable Mobility Scholarship at University West in Sweden. Bidding on the car opens soon, and interested parties can sign up to be alerted when the auction starts.   Auto News Auctions Saab Sedan

What would you drive in 1985?

Bereft of live baseball games to watch, I've turned to the good ship YouTube to watch classic games. While watching the 1985 American League Championship Series last night, several of the broadcast's commercials made its way into the original VHS recording, including those for cars. "Only 8.8% financing on a 1985 Ford Tempo!" What a deal! That got me thinking: what would I drive in 1985?  It sure wouldn't be a Tempo. Or an IROC-Z, for that matter, despite what my Photoshopped 1980s self would indicate in the picture above. I posed this question to my fellow Autobloggists. Only one could actually drive back then, I was only 2 and a few editors weren't even close to being born. Here are our choices, which were simply made with the edict of "Come on, man, be realistic."  West Coast Editor James Riswick: OK, I started this, I'll go first. I like coupes today, so I'm pretty sure I'd drive one back then. I definitely don't see myself driving some badge-engineered GM thing from 1985, and although a Honda Prelude has a certain appeal, I must admit that something European would likely be in order. A BMW maybe? No, I'm too much a contrarian for that. The answer is therefore a 1985 Saab 900 Turbo 3-Door, which is not only a coupe but a hatchback, too. If I could scrounge up enough Reagan-era bucks for the ultra-cool SPG model, that would be rad. The 900 Turbo pictured, which was for auction on Bring a Trailer a few years ago, came with plum-colored Bokhara Red, and you're damn sure I would've had me one of those. Nevermind 1985, I'd probably drive this thing today.   Associate Editor Byron Hurd: I'm going to go with the 1985.5 Ford Mustang SVO, AKA the turbocharged Fox Body that everybody remembers but nobody drives. The mid-year update to the SVO bumped the power up from 175 ponies (yeah, yeah) to 205, making it almost as powerful (on paper, anyway) as the V8-powered GT models offered in the same time frame. I chose this particular car because it's a bit of a time capsule and, simultaneously, a reminder that all things are cyclical. Here we are, 35 years later, and 2.3-liter turbocharged Mustangs are a thing again. Who would have guessed?

NEVS, the company that took over Saab, gets new majority owner

Chinese real estate conglomerate Evergrande Group, a key investor behind troubled electric vehicle startup Faraday Future, has acquired a 51 percent stake in NEVS. That's the Chinese-backed Swedish electric vehicle company that purchased the assets of Saab out of bankruptcy in 2012. The investment by subsidiary Evergrande Health Industry Group was valued at the equivalent of $930 million and is expected to help NEVS develop new EVs. Evergrande said it paid the first installment of $430 million on Jan. 15, with the remainder due by the end of the month. The remaining 49 percent stake is controlled by a holding company controlled by NEVS founder Kai Johan Jiang. "It means that NEVS will get a financial (sic) strong main owner who is very interested in developing our vision about green mobility transport solutions for the future," NEVS CEO Stefan Tilk said in a statement. NEVS, short for National Electric Vehicle Sweden, owns production facilities in Trollhattan, Sweden, and Tianjin, China, with another under construction in Shanghai. In late 2017 the company launched what apparently was limited production of the 9-3 EV, an electric vehicle based — you guessed it — on the old Saab 9-3 platform. The company now says it will be built in Tianjin starting later this year, with components coming from Trollhattan. It boasts a 186-mile range, in-car WiFi and a cabin air filter for the notoriously smoggy Chinese air. It also showed a battery-electric 9-3X concept at CES Asia in 2017, which is likely to be its next model pegged for production. The South China Morning Post, citing local media reports, says two of NEVS' models meet the standards for mass production in China. This content is hosted by a third party. To view it, please update your privacy preferences. Manage Settings. Definitely the best promotional video we've ever seen. Evergrande Health first came to Faraday Future's rescue back in 2017 with a promised $2 billion investment, but the two sides later went into arbitration in Hong Kong over a dispute about money following the first infusion of $800 million, leading the automaker to cut staff and wages last year, casting the future of FF into doubt. At the end of 2018, Faraday announced it had entered into a new restructuring agreement with an Evergrande Health subsidiary that sees them end litigation and jettison the previous investment agreement, taking Evergrande's investment in the company to 32 percent.